ROS1 in Squamous Non-Small Cell Lung Cancer—Combined Immunotherapy (PD1/CTLA4) or Targeted Therapy?

摘要: ROS1 oncogenic fusion is reported to be 1% - 2% of non-small cell lung cancers (NSCLCs) the adenocarcinoma subgroup. Meanwhile, there are no records squamous cancer patients with tumors harboring fusions. The Foundation Medicine database indicates a frequency rearrangements 0.2% among NSCLC. Crizotinib is known very effective in these patients. Here we present a non-smoker patient who had pure squamous NSCLC that was treated by combinational immunotherapy under clinical trial and progressed after 2 cycles. Surprisingly, comprehensive genomic profiling detected rare EZR-ROS1 fusion, was treated crizotinib with significant response within 6 weeks. To date, the patient has been on therapy for 42 months has achieved complete metabolic response.